Conclusions
While initially MR expression was thought to be restricted to kidney
epithelial cells, numerous translational studies have shed light on the
complex (patho-)physiological importance of MR expression in many CV
cells such as cardiomyocytes, endothelial cells and VSMCs. MRA are an
essential part of medical therapy for HF and resistant hypertension for
many years. Currently the novel non-steroidal MRA finerenone is
introduced into clinical practice for patients with diabetic kidney
disease to reduce both progression of renal disease and CV events.